CoChat

Human regulatory T cells are selectively activated by low‐dose application of the CD28 superagonist TGN1412/TAB08

Open access

The DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index, and 1 are not checked yet.

Abstract

CD28 superagonists (CD28SAs) are potent T‐cell‐activating monoclonal antibodies (mAbs). In contrast to their benign behavior and marked therapeutic efficacy as activators of regulatory T (Treg) cells in preclinical rodent models, a phase I trial of the human CD28SA TGN1412 (now called TAB08) in 2006 resulted in a life‐threatening cytokine release syndrome (CRS). We studied TAB08‐mediated Treg‐cell activation in a recently developed in vitro system of human PBMCs, which also reproduces the CRS experienced by the healthy volunteers. We show that just as in rodents, CD28SAs are potent activators and expanders of Treg cells from healthy donors and rheumatoid arthritis patients, even under effective blockade of pro‐inflammatory cytokine release by a corticosteroid. Moreover, CD28SA titration identifies a dose range where pro‐inflammatory cytokine secretion from conventional T cells is absent while appreciable Treg‐cell activation is maintained. Finally, we report that low‐dose application of TAB08 to healthy volunteers results in dose‐dependent systemic release of the Treg‐cell signature cytokine IL‐10 in the absence of the pro‐inflammatory factors associated with the CRS of the 2006 TGN1412 study. These results demonstrate the potential of appropriately dosed CD28SA and corticosteroid comedication to mobilize human Treg cells for the treatment of autoimmune and inflammatory conditions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/eji.201343967

Cites

48 of 49 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Induction of T-cell proliferation and cytokine production by the CD28SA TAB08 in human PBMCs and sensitivity to suppression by the corticosteroid analogue MP. HD precultured (1 × 10 7 cells/mL for 48 h) PBMCs were cultured in 0.2 mL AB medium at 1 × 10 6 cells/mL in 96-well flatbottom tissue culture plates. (A and B) T-cell proliferation was measured as incorporated 3 H thymidine on day 2-3 poststimulation with (A) the indicated concentrations of TAB08 and (B) 1 μ g/mL of TAB08 in the presence of titrated concentrations of MP. (C-E) Supernatants from cells stimulated as in (A) were collected 24 h poststimulation and analyzed for the presence of the indicated cytokines by CBA. (F) Suppression of TAB08 (1 μ g/mL) induced cytokine release by titrated concentrations of MP was calculated as percent of control release in the absence of MP. Data in (A-E) are shown as mean ± SD of three triplicate samples from one of three independent experiments with similar results.
Figure 1 Induction of T-cell proliferation and cytokine production by the CD28SA TAB08 in human PBMCs and sensitivity to suppression by the corticosteroid analogue MP. HD precultured (1 × 10 7 cells/mL for 48 h) PBMCs were cultured in 0.2 mL AB medium at 1 × 10 6 cells/mL in 96-well flatbottom tissue culture plates. (A and B) T-cell proliferation was measured as incorporated 3 H thymidine on day 2-3 poststimulation with (A) the indicated concentrations of TAB08 and (B) 1 μ g/mL of TAB08 in the presence of titrated concentrations of MP. (C-E) Supernatants from cells stimulated as in (A) were collected 24 h poststimulation and analyzed for the presence of the indicated cytokines by CBA. (F) Suppression of TAB08 (1 μ g/mL) induced cytokine release by titrated concentrations of MP was calculated as percent of control release in the absence of MP. Data in (A-E) are shown as mean ± SD of three triplicate samples from one of three independent experiments with similar results.CC-BY-NC-ND · From the PDF
Figure 2 TAB08-induced expansion and proliferation of Treg cells in the absence and presence of MP. (A) HD (1 × 10 7 cells/mL for 48 h) precultured PBMCs were cultured in 0.6 mL AB medium for 5 days at 1 × 10 6 cells/mL in 48-well flat-bottom tissue culture plates with varying concentrations of TAB08 . Treg-cell (CD25 hi Foxp3 + ) and activated Tconv-cell (CD25 lo Foxp3 -) frequencies among gated CD4 + T cells were then assessed by flow cytometry using a live light-scatter entrance gate. (B) Cells were stimulated as in (A), in the presence or absence of 0.01 mM MP. Treg-cell frequencies among CD4 + T cells and absolute numbers of Treg cells were determined by flow cytometry after 5 days of culture. (C) HD precultured PBMCs were CFSE-labeled with and without depletion of CD25 + cells, and cocultured (1:1) with unlabelled HD precultured PBMCs and 1 μ g/mL TAB08 for 3 days. Treg-cell versus Tconv-cell expansion in CD25-depleted and nondepleted PBMC cultures was then assessed by flow cytometry, using a live light-scatter entrance gate followed by gates for CD4 + Foxp3 -(left dot plots) and CD4 + Foxp3 + (right dot plots). (D-E) Proliferation of Treg cells versus Tconv cells after stimulation with varying concentrations of TAB08 in the presence and absence of 0.01 mM MP. Proliferation was assessed by (D) the expression of Ki67 and (E) CFSE dilution. * denotes insufficient number of cells for evaluation. Data in (B, C, and E) are shown as mean ± SD of three samples from one experiment taken from three independent experiments with similar results. Flow cytometry data are representative of three independent experiments.
Figure 2 TAB08-induced expansion and proliferation of Treg cells in the absence and presence of MP. (A) HD (1 × 10 7 cells/mL for 48 h) precultured PBMCs were cultured in 0.6 mL AB medium for 5 days at 1 × 10 6 cells/mL in 48-well flat-bottom tissue culture plates with varying concentrations of TAB08 . Treg-cell (CD25 hi Foxp3 + ) and activated Tconv-cell (CD25 lo Foxp3 -) frequencies among gated CD4 + T cells were then assessed by flow cytometry using a live light-scatter entrance gate. (B) Cells were stimulated as in (A), in the presence or absence of 0.01 mM MP. Treg-cell frequencies among CD4 + T cells and absolute numbers of Treg cells were determined by flow cytometry after 5 days of culture. (C) HD precultured PBMCs were CFSE-labeled with and without depletion of CD25 + cells, and cocultured (1:1) with unlabelled HD precultured PBMCs and 1 μ g/mL TAB08 for 3 days. Treg-cell versus Tconv-cell expansion in CD25-depleted and nondepleted PBMC cultures was then assessed by flow cytometry, using a live light-scatter entrance gate followed by gates for CD4 + Foxp3 -(left dot plots) and CD4 + Foxp3 + (right dot plots). (D-E) Proliferation of Treg cells versus Tconv cells after stimulation with varying concentrations of TAB08 in the presence and absence of 0.01 mM MP. Proliferation was assessed by (D) the expression of Ki67 and (E) CFSE dilution. * denotes insufficient number of cells for evaluation. Data in (B, C, and E) are shown as mean ± SD of three samples from one experiment taken from three independent experiments with similar results. Flow cytometry data are representative of three independent experiments.CC-BY-NC-ND · From the PDF
Image 3
CC-BY-NC-ND · From the PDF
Image 4
CC-BY-NC-ND · From the PDF
Figure 4 Suppressive activity of TAB08-expanded Treg cells. (A) Treg cells were purified from HD precultured PBMCs stimulated for 5 days with TAB08 (1 or 0.1 μ g/mL) in the presence or absence of 0.01 mM MP, and cocultured with purified CFSE-labeled CD4 + T cells, monocytes, and anti-CD3 as detailed in Materials and methods. Proliferation was determined by flow cytometry on day 3 and is shown as percentage of divided indicator cells. (B) Cell cultures from (A) were analyzed by CBA for the presence of the indicated cytokines at 24 h of culture. '0.01 mM MP' above bars indicates MP inclusion during Treg-cell expansion, not during the suppression assay. Data in (A) show single measurements of pooled cells recovered from three parallel cultures, data in (B) are shown as mean ± SD of individual cytokine measurements from the supernatants of these three parallel cultures. Data are representative of three independent experiments with similar results.
Figure 4 Suppressive activity of TAB08-expanded Treg cells. (A) Treg cells were purified from HD precultured PBMCs stimulated for 5 days with TAB08 (1 or 0.1 μ g/mL) in the presence or absence of 0.01 mM MP, and cocultured with purified CFSE-labeled CD4 + T cells, monocytes, and anti-CD3 as detailed in Materials and methods. Proliferation was determined by flow cytometry on day 3 and is shown as percentage of divided indicator cells. (B) Cell cultures from (A) were analyzed by CBA for the presence of the indicated cytokines at 24 h of culture. '0.01 mM MP' above bars indicates MP inclusion during Treg-cell expansion, not during the suppression assay. Data in (A) show single measurements of pooled cells recovered from three parallel cultures, data in (B) are shown as mean ± SD of individual cytokine measurements from the supernatants of these three parallel cultures. Data are representative of three independent experiments with similar results.CC-BY-NC-ND · From the PDF
Figure 5 Corticosteroid sensitivity of TNG1412-induced cytokine release in PBMCs from RA patients. HD precultured PBMCs from RA patients were cultured in 0.6 mL medium for 5 days at 1 × 10 6 cells/mL in 48-well flat-bottom tissue culture plates. PBMCs were stimulated with 1, 0.1, and 0.06 μ g/mL TAB08, and 0.01 mM MP was used for suppression of cytokine release ( n = 10). A total of 0.1 mL supernatant was removed for cytokine analysis after 24 h. Each symbol represents a triplicate mean value obtained with parallel cultures set up from one blood sample. Data obtained with several (up to three) blood samples taken from the same donor at least 2 weeks apart share the same symbol. Means of all patients per condition are indicated by the horizontal bars. For patient characteristics, see Supporting Information Table 1. **** p ≤ 0.0001, *** p ≤ 0.0009, ** p ≤ 0.0081, * p ≤ 0.0385 (Friedman test). IFNγ , IL-4, IL-10, and IL-17A: no significant difference between groups.
Figure 5 Corticosteroid sensitivity of TNG1412-induced cytokine release in PBMCs from RA patients. HD precultured PBMCs from RA patients were cultured in 0.6 mL medium for 5 days at 1 × 10 6 cells/mL in 48-well flat-bottom tissue culture plates. PBMCs were stimulated with 1, 0.1, and 0.06 μ g/mL TAB08, and 0.01 mM MP was used for suppression of cytokine release ( n = 10). A total of 0.1 mL supernatant was removed for cytokine analysis after 24 h. Each symbol represents a triplicate mean value obtained with parallel cultures set up from one blood sample. Data obtained with several (up to three) blood samples taken from the same donor at least 2 weeks apart share the same symbol. Means of all patients per condition are indicated by the horizontal bars. For patient characteristics, see Supporting Information Table 1. **** p ≤ 0.0001, *** p ≤ 0.0009, ** p ≤ 0.0081, * p ≤ 0.0385 (Friedman test). IFNγ , IL-4, IL-10, and IL-17A: no significant difference between groups.CC-BY-NC-ND · From the PDF
Figure 6 TAB08-expanded Treg cells from RA patients are functional suppressor cells. (A-E) Cultures described in Fig. 5 were harvested and analyzed by flow cytometry on day 5 for (A and B) Treg-cell expansion, (C and D) proliferation (Ki67 expression) of Treg and Tconv CD4 + T cells, (E) CTLA-4 expression (intracellular and surface) by Treg cells (CD4 + CD25 hi Foxp3 + ) versus Tconv cells (CD4 + Foxp3 -cells) using the same gating strategy as in Figs. 1-3. (F) Suppression of anti-CD3-stimulated proliferation of CFSE-labeled CD4 + T cells by TAB08 (0.06 μ g/mL) expanded Treg cells from RA patient 7. Percentage of divided indicator cells was determined by flow cytometry on day 3 of culture. Experimental setup was as in Fig. 4A. (G) Supernatants from cultures in (F) were analyzed by CBA for the presence of cytokines after 24 h of stimulation. (A-E) Each symbol represents a triplicate mean value obtained with parallel cultures set up from one blood sample. Data obtained with several (up to three) blood samples taken from the same donor at least 2 weeks apart share the same symbol. Means of all patients per condition are indicated by the horizontal bars. **** p ≤ 0.0001, *** p ≤ 0.0007, ** p ≤ 0.0062, * p ≤ 0.0412 (Friedman test). (A and C) n = 10, (B) n = 8, (D) n = 7, (E) n = 6. (F and G) Data are shown as mean + SD of triplicate samples from one randomly chosen patient. Results are similar to three experiments performed with healthy donors.
Figure 6 TAB08-expanded Treg cells from RA patients are functional suppressor cells. (A-E) Cultures described in Fig. 5 were harvested and analyzed by flow cytometry on day 5 for (A and B) Treg-cell expansion, (C and D) proliferation (Ki67 expression) of Treg and Tconv CD4 + T cells, (E) CTLA-4 expression (intracellular and surface) by Treg cells (CD4 + CD25 hi Foxp3 + ) versus Tconv cells (CD4 + Foxp3 -cells) using the same gating strategy as in Figs. 1-3. (F) Suppression of anti-CD3-stimulated proliferation of CFSE-labeled CD4 + T cells by TAB08 (0.06 μ g/mL) expanded Treg cells from RA patient 7. Percentage of divided indicator cells was determined by flow cytometry on day 3 of culture. Experimental setup was as in Fig. 4A. (G) Supernatants from cultures in (F) were analyzed by CBA for the presence of cytokines after 24 h of stimulation. (A-E) Each symbol represents a triplicate mean value obtained with parallel cultures set up from one blood sample. Data obtained with several (up to three) blood samples taken from the same donor at least 2 weeks apart share the same symbol. Means of all patients per condition are indicated by the horizontal bars. **** p ≤ 0.0001, *** p ≤ 0.0007, ** p ≤ 0.0062, * p ≤ 0.0412 (Friedman test). (A and C) n = 10, (B) n = 8, (D) n = 7, (E) n = 6. (F and G) Data are shown as mean + SD of triplicate samples from one randomly chosen patient. Results are similar to three experiments performed with healthy donors.CC-BY-NC-ND · From the PDF
Figure 7 Cytokine response of healthy volunteers to TAB08 infusion. Samples of peripheral blood were taken from healthy volunteers before and at various time points after infusion with TAB08 at the doses indicated (infusion with 0.1 μ g/kg: n = 6, infusion with 0.3, 0.6, 1, 1.5, 2, 3, 5, and 7 μ g/kg: n = 3). Infusions were performed over 4, 8, or 12 h as detailed in Materials and methods. Plasma was isolated via centrifugation and kept at -80 ◦ C until analysis. (A) Serum levels of TNF, IFNγ , IL-2, and IL-10 of all participants. Cytokines were measured by Enhanced Sensitivity CBA. (B) Dose-dependent release of IL-10 at 12 h after TAB08 infusion. Data are shown as mean ± SD of the IL-10 serum levels of the participants in each cohort. * p ≤ 0.03 (unpaired t -test).
Figure 7 Cytokine response of healthy volunteers to TAB08 infusion. Samples of peripheral blood were taken from healthy volunteers before and at various time points after infusion with TAB08 at the doses indicated (infusion with 0.1 μ g/kg: n = 6, infusion with 0.3, 0.6, 1, 1.5, 2, 3, 5, and 7 μ g/kg: n = 3). Infusions were performed over 4, 8, or 12 h as detailed in Materials and methods. Plasma was isolated via centrifugation and kept at -80 ◦ C until analysis. (A) Serum levels of TNF, IFNγ , IL-2, and IL-10 of all participants. Cytokines were measured by Enhanced Sensitivity CBA. (B) Dose-dependent release of IL-10 at 12 h after TAB08 infusion. Data are shown as mean ± SD of the IL-10 serum levels of the participants in each cohort. * p ≤ 0.03 (unpaired t -test).CC-BY-NC-ND · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 49 references

Cited by

See all 97

Metadata

Authors
Tabares, P., Berr, S., Römer, P. S., Chuvpilo, S., Matskevich, A. A., Tyrsin, D., Fedotov, Y., Einsele, H., Tony, H., & Hünig, T.
Affiliations
  • University of Würzburg (DE)
  • TheraMAB LLC Würzburg Germany
  • TheraMAB LLC Moscow Russian Federation
  • Universitätsklinikum Würzburg (DE)
Corresponding author
Hünig, Thomas
Venue
European Journal of Immunology
Publisher
Wiley
Published
2014-02
Volume
44
Issue
4
Pages
1225-1236
ISSN
  • 0014-2980 (ISSN-L)
  • 1521-4141
OpenAlex
W1570409954
Cited by
97
References
48
Citations by year
2026: 1 · 2025: 1 · 2024: 8 · 2023: 3 · 2022: 2 · 2021: 4 · 2020: 7 · 2019: 8 · 2018: 10 · 2017: 9 · 2016: 16 · 2015: 17 · 2014: 11
FWCI
8.11
Type
journal article
Language
en
Open access
Locations
  • European Journal of Immunology (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • Deutsche Forschungsgemeinschaft (SFB-TR52)
  • TheraMab LLC
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Keywords
regulatory T cells, TGN1412, cytokine release syndrome, low-dose immunotherapy, IL-10, rheumatoid arthritis, autoimmune disease therapy, dose titration, human peripheral blood mononuclear cells
MeSH terms
Adrenal Cortex Hormones, Arthritis, Rheumatoid, Cells, Cultured, Dose-Response Relationship, Drug, Flow Cytometry, Humans, Leukocytes, Mononuclear, Lymphocyte Activation, Cytokines, Interleukin-10, CD28 Antigens, Inflammation Mediators, Cell Proliferation, T-Lymphocytes, Regulatory, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Human regulatory T cells are selectively activated by low‐dose application of the CD28 superagonist TGN1412/TAB08. https://app.cochat.ai/papers/10.1002/eji.201343967
The paper
Tabares, P., Berr, S., Römer, P. S., Chuvpilo, S., Matskevich, A. A., Tyrsin, D., Fedotov, Y., Einsele, H., Tony, H., & Hünig, T. (2014). Human regulatory T cells are selectively activated by low‐dose application of the CD28 superagonist TGN1412/TAB08. European Journal of Immunology. https://doi.org/10.1002/eji.201343967

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.